When prostate cancer patients need therapy to reduce male hormone levels, delivering some of the treatment via a patch on the ...

Bayer is committed to advancing treatment in prostate cancer care, showcasing new analyses from its comprehensive clinical trial program for NUBEQA ® (darolutamide), which includes the ARANOTE, ...

A paper inadvertently published on the website of an ASCO conference revealed good results for mevrometostat in treating ...

Savita Dandapani, MD, PhD, discusses the rationale behind a study evaluating the combination of radium-223, hormone therapy, and SBRT in metastatic castration-sensitive prostate cancer.

Untreated prostate cancer can sometimes cause erectile dysfunction (ED). However, ED is more commonly associated with ...

As you navigate the challenges of prostate cancer and erectile dysfunction, remember that you are not alone. With advances in ...

ADT, androgen-deprivation therapy; DOC, docetaxel; FDA, US Food and Drug Administration; mHSPC, metastatic hormone-sensitive prostate cancer; RCT, randomized controlled trial. We considered the ...

Treatment of metastatic hormone-sensitive prostate cancer (mHSPC) has evolved with robust clinical trial evidence on the benefits of combining androgen-deprivation therapy (ADT) with androgen receptor ...

Kairos Pharma (NYSE American: KAPA) has added Huntsman Cancer Institute in Salt Lake City as a site for its Phase 2 clinical trial of ENV105 for cas ...

On Feb. 1, Novartis Pharmaceuticals Canada Inc. announced that the Nova Scotia government is funding Pluvicto injections for ...

The intended therapeutic effect of gonadotropin-releasing-hormone (GnRH) agonists is hypogonadism, which is a leading cause of osteoporosis in men. Observations are consistent with this effect ...

ASCO Genitourinary Cancers Symposium approaches, several highly anticipated studies are set to shape the future of treatment ...